Welcome to the first of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?” Transactions involving digital assets are becoming an increasing focus for pharmaceutical companies. In this series, life sciences industry M&A veteran and Sterling Technology board advisor John Easton will discuss how these differ from traditional life science deals, and what both parties should look out for to increase the chances of deal success, mitigate risks, and avoid failure.
In this first episode we consider cultural differences between life science and technology companies and the implications those differences have for digital dealmaking. You can also learn more by downloading our report which accompanies this podcast series.
